InMed Pharmaceuticals (INM) Revenue & Revenue Breakdown
InMed Pharmaceuticals Revenue Highlights
Latest Revenue (Y)
$6.56B
Latest Revenue (Q)
$2.06B
InMed Pharmaceuticals Revenue by Period
InMed Pharmaceuticals Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-06-30 | $6.56B | 601968.87% |
| 2022-06-30 | $1.09M | 100.00% |
| 2021-06-30 | - | 100.00% |
| 2020-06-30 | - | 100.00% |
| 2019-06-30 | - | 100.00% |
| 2018-06-30 | - | 100.00% |
| 2017-06-30 | - | 100.00% |
| 2016-06-30 | - | 100.00% |
| 2015-06-30 | - | 100.00% |
| 2014-06-30 | - | 100.00% |
| 2013-06-30 | - | 100.00% |
| 2012-06-30 | - | -100.00% |
| 2011-06-30 | $39.66K | -50.09% |
| 2010-06-30 | $79.46K | -52.82% |
| 2009-06-30 | $168.42K | -72.98% |
| 2008-06-30 | $623.37K | -64.11% |
| 2007-06-30 | $1.74M | -37.01% |
| 2006-06-30 | $2.76M | -34.85% |
| 2005-06-30 | $4.23M | 102.27% |
| 2004-07-31 | $2.09M | 1027.38% |
| 2003-07-31 | $185.61K | 1248.04% |
| 2002-07-31 | $13.77K | 463.69% |
| 2001-07-31 | $2.44K | - |
InMed Pharmaceuticals generated $6.56B in revenue during NA 2023, up 601968.87% compared to the previous quarter, and up Infinity% compared to the same period a year ago.
InMed Pharmaceuticals Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-03-31 | $2.06B | 165659.07% |
| 2023-12-31 | $1.24M | -26.60% |
| 2023-09-30 | $1.69M | -26.89% |
| 2023-06-30 | $2.31M | 123.52% |
| 2023-03-31 | $1.03M | 120.09% |
| 2022-12-31 | $469.78K | 46.45% |
| 2022-09-30 | $320.79K | -37.68% |
| 2022-06-30 | $514.76K | 66.27% |
| 2022-03-31 | $309.58K | 16.78% |
| 2021-12-31 | $265.09K | 100.00% |
| 2021-09-30 | - | 100.00% |
| 2021-06-30 | - | 100.00% |
| 2021-03-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2020-09-30 | - | 100.00% |
| 2020-06-30 | - | 100.00% |
| 2020-03-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2019-09-30 | - | 100.00% |
| 2019-06-30 | - | 100.00% |
| 2019-03-31 | - | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2018-09-30 | - | 100.00% |
| 2018-06-30 | - | 100.00% |
| 2018-03-31 | - | 100.00% |
| 2017-12-31 | - | 100.00% |
| 2017-09-30 | - | 100.00% |
| 2017-06-30 | - | 100.00% |
| 2017-03-31 | - | 100.00% |
| 2016-12-31 | - | 100.00% |
| 2016-09-30 | - | 100.00% |
| 2016-06-30 | - | 100.00% |
| 2016-03-31 | - | 100.00% |
| 2015-12-31 | - | 100.00% |
| 2015-09-30 | - | 100.00% |
| 2015-06-30 | - | 100.00% |
| 2015-03-31 | - | 100.00% |
| 2014-12-31 | - | 100.00% |
| 2014-09-30 | - | 100.00% |
| 2014-06-30 | - | 100.00% |
| 2014-03-31 | - | 100.00% |
| 2013-12-31 | - | 100.00% |
| 2013-09-30 | - | 100.00% |
| 2013-06-30 | - | 100.00% |
| 2013-03-31 | - | 100.00% |
| 2012-12-31 | - | 100.00% |
| 2012-09-30 | - | 100.00% |
| 2012-06-30 | - | 100.00% |
| 2012-03-31 | - | 100.00% |
| 2011-12-31 | - | 100.00% |
| 2011-09-30 | - | -100.00% |
| 2011-06-30 | $138.33 | -99.33% |
| 2011-03-31 | $20.78K | 128.68% |
| 2010-12-31 | $9.09K | 2.82% |
| 2010-09-30 | $8.84K | -82.89% |
| 2010-06-30 | $51.66K | 721.74% |
| 2010-03-31 | $6.29K | 113.95% |
| 2009-12-31 | $2.94K | -83.34% |
| 2009-09-30 | $17.64K | -41.52% |
| 2009-06-30 | $30.16K | 238.31% |
| 2009-03-31 | $8.92K | -72.88% |
| 2008-12-31 | $32.88K | -71.77% |
| 2008-09-30 | $116.48K | -118.92% |
| 2008-06-30 | $-615.65K | - |
InMed Pharmaceuticals generated $2.06B in revenue during Q3 2024, up 165659.07% compared to the previous quarter, and up 437594.38% compared to the same period a year ago.
InMed Pharmaceuticals Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| INM | InMed Pharmaceuticals | $6.56B | $2.06B |
| SGTX | Sigilon Therapeutics | $12.94M | $5.90M |
| TNXP | Tonix Pharmaceuticals | $7.77M | $2.21M |
| BDRX | Biodexa Pharmaceuticals | $381.00K | $41.50K |
| PALI | Palisade Bio | $250.00K | - |
| SONN | Sonnet BioTherapeutics | $147.81K | - |
| VRAX | Virax Biolabs Group | $8.56K | $76.50K |
| REVB | Revelation Biosciences | - | - |
| ICU | SeaStar Medical | - | - |
| ATNF | 180 Life Sciences | - | - |
| DRUG | Bright Minds Biosciences | - | - |
| GOVX | GeoVax Labs | - | - |
| PHIO | Phio Pharmaceuticals | - | - |
| ZVSA | ZyVersa Therapeutics | - | - |
| IMMX | Immix Biopharma | - | - |
| ALLR | Allarity Therapeutics | - | - |
| VIRI | Virios Therapeutics | - | - |
| QNRX | Quoin Pharmaceuticals | - | - |
INM Revenue FAQ
What is InMed Pharmaceuticals’s yearly revenue?
InMed Pharmaceuticals's yearly revenue for 2023 was $6.56B, representing an increase of 601968.87% compared to 2022. The company's yearly revenue for 2022 was $1.09M, representing an increase of 100.00% compared to 2021. INM's yearly revenue for 2021 was $0, representing an increase of 100.00% compared to 2020.
What is InMed Pharmaceuticals’s quarterly revenue?
InMed Pharmaceuticals's quarterly revenue for Q3 2024 was $2.06B, a 165659.07% increase from the previous quarter (Q2 2024), and a 198729.12% increase year-over-year (Q3 2023). The company's quarterly revenue for Q2 2024 was $1.24M, a -26.60% decrease from the previous quarter (Q1 2024), and a 163.99% increase year-over-year (Q2 2023). INM's quarterly revenue for Q1 2024 was $1.69M, a -26.89% decrease from the previous quarter (Q4 2023), and a 426.69% increase year-over-year (Q1 2023).
What is InMed Pharmaceuticals’s revenue growth rate?
InMed Pharmaceuticals's revenue growth rate for the last 3 years (2021-2023) was 0%, and for the last 5 years (2019-2023) was 0%.